Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on January 09, 2026.
The company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
Salarius Pharmaceuticals, Inc.'s stock currently trades at $0.00 with a market capitalization of $0.